Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Annovis Bio Inc ANVS

Healthcare Biotechnology
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced... see more

Recent & Breaking News (NYSE:ANVS)

Annovis Bio Appoints Andrew Walsh as Vice President Finance

GlobeNewswire December 1, 2023

Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original Projections

GlobeNewswire November 27, 2023

Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 8, 2023

Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson's Patients

Business Wire November 2, 2023

Annovis Bio Announces Pricing of $7.5 Million Public Offering

Business Wire October 31, 2023

Annovis Bio Announces Launch of Proposed Public Offering

Business Wire October 30, 2023

Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer's Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)

Business Wire October 30, 2023

Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference

Business Wire October 24, 2023

Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer's Study

GlobeNewswire October 12, 2023

Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Business Wire August 15, 2023

Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference

Business Wire July 18, 2023

Annovis Bio Announces the Filing of a Groundbreaking Patent

Business Wire June 27, 2023

Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson's Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)

Business Wire June 20, 2023

Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace

PR Newswire June 8, 2023

Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire May 11, 2023

Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans

GlobeNewswire April 27, 2023

ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST

PR Newswire April 20, 2023

ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST

PR Newswire April 19, 2023

ANNOVIS BIO TO HOLD LIVE WEBCAST TO REVIEW ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE CLINICAL PROGRAMS

PR Newswire April 13, 2023

ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION

PR Newswire April 11, 2023